January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
2 citations
,
June 1985 in “PubMed” Ethylenthiourea is toxic to the liver and nervous system, especially with alcohol.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
1 citations
,
December 2012 in “I P Pavlov Russian Medical Biological Herald” Finasteride increases P-glycoprotein activity in the liver and kidney.
6 citations
,
August 2024 in “The Journal of Dermatology” Ozenoxacin reduces sebum production, helping manage acne.
January 2013 in “International journal of contemporary surgery” Using Cyproterone Acetate with Eflornithine together is safe and works better for treating facial hair in women.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
3 citations
,
January 2015 in “Indian journal of paediatric dermatology” Oral isotretinoin temporarily improved skin symptoms in a child with IFAP syndrome.
5 citations
,
September 2014 in “Journal of Pharmaceutical Sciences” 19 citations
,
November 1979 in “Archives of dermatology” Tretinoin may be effective for treating Fox-Fordyce disease.
4 citations
,
January 1987 in “Beiträge zur Onkologie/Contributions to oncology” Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.
September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
The research developed new fortilin protein constructs for potential heart disease treatments.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
1 citations
,
January 2024 in “Surgical & Cosmetic Dermatology” Botulinum toxin A helped a patient recover from dissecting folliculitis when antibiotics failed.
April 2017 in “Journal of Investigative Dermatology” Fisetin may help treat psoriasis and reduce skin inflammation.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly” 18 citations
,
October 2015 in “Journal of the European Academy of Dermatology and Venereology” Topical eflornithine helps maintain hair reduction after IPL therapy in women with facial hirsutism.
39 citations
,
October 2015 in “Case Reports” Some people experience severe, long-lasting side effects from fluoroquinolone antibiotics, leading to the recommendation of limited use and increased awareness of these risks.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
January 2016 in “Refubium (Universitätsbibliothek der Freien Universität Berlin)” CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.